Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018

Abstract

Cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) is increasingly common, while its prevalence in the U.S. is unknown. We utilized data from 10 National Health and Nutrition Examination Survey (NHANES) two-year cycles in U.S. adults from 1999 to 2018. We reported the age-standardized prevalence of cardiometabolic multimorbidity in 2017–2018 and analyzed their trends during 1999–2018 with joinpoint regression models. Stratified analyses were performed according to gender, age, and race/ethnicity. In 2017–2018, the prevalence of cardiometabolic multimorbidity was 14.4% in the U.S., and it was higher among male, older, and non-Hispanic Black people. The three most common patterns were hypertension and diabetes (7.5%); hypertension, diabetes, and CHD (2.2%); and hypertension and CHD (1.8%). During 1999–2018, the prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly, with an averaged two-year cycle percentage change (AAPC) of 3.6 (95% CI: 2.1 to 5.3). The increasing trend was significant for both genders, most age groups except for 60–79 years, and non-Hispanic White people. For common patterns, the trend was increasing for hypertension and diabetes and hypertension, diabetes, and CHD, while it was decreasing for hypertension and CHD. Our findings provide evidence that cardiometabolic multimorbidity has risen as an austere issue of public health in the U.S.

Cardiometabolic Diseases and Quality-of-Life Outcomes in Adults With HIV in the Deep South: A Cross-sectional Study

“…Cardiometabolic diseases were self-reported by participants based on the question, “Has a doctor or a nurse ever told you that you have…?” The six CMDs assessed included hypertension/high blood pressure, congestive heart failure, stroke/mini stroke/transient ischemic attack (TIA), angina or chest pain due to heart disease, diabetes mellitus, and high cholesterol. The decision to include these specific cardiovascular and metabolic chronic conditions was based on their significance as cardiometabolic diseases in previously published studies (Cheng et al, 2022; Willig et al, 2020; Yang et al, 2019), as well as availability of data in the current study. Participants who answered “don't know” or “refused” were classified as missing and excluded from the study.…”

Linoleic acid, an omega-6 fatty acid that reduces risk for cardiometabolic diseases: premise, promise and practical implications

“…Currently, one half of adults over age 60 years in the United States have CMD [9]. T2DM is growing fastest in underdeveloped countries where worldwide age-adjusted prevalence may reach 11.2% of adults [10].…”

General Public’s knowledge, awareness, and perception of Cardiometabolic diseases: data from a Singapore study population

“…The rising cardiometabolic disease epidemic is a global health concern, with worrisome trends of disease burden and morbidity over the past decades (1)(2)(3). In Asia, nearly a fifth of the adult population is affected by cardiometabolic diseases (4).…”